Financial Statements
Bayer Group Consolidated Statements of Income
| Note | 2006 | 2007 | |
| € million | |||
| Net sales | [7] | 28,956 | 32,385 |
| Cost of goods sold | (15,275) | (16,352) | |
| Gross profit | 13,681 | 16,033 | |
| Selling expenses | [8] | (6,534) | (7,782) |
| Research and development expenses | [9] | (2,297) | (2,578) |
| General administration expenses | (1,599) | (1,772) | |
| Other operating income | [10] | 730 | 822 |
| Other operating expenses | [11] | (1,219) | (1,569) |
| Operating result [EBIT] | 2,762 | 3,154 | |
| Equity-method loss | [13.1] | (25) | (45) |
| Non-operating income | 931 | 834 | |
| Non-operating expenses | (1,688) | (1,709) | |
| Non-operating result | [13] | (782) | (920) |
| Income before income taxes | 1,980 | 2,234 | |
| Income taxes | [14] | (454) | 72 |
| Income from continuing operations after taxes | 1,526 | 2,306 | |
| Income from discontinued operations after taxes | [6.3] | 169 | 2,410 |
| Income after taxes | 1,695 | 4,716 | |
| of which attributable to minority interest | [15] | 12 | 5 |
| of which attributable to Bayer AG stockholders (net income) | 1,683 | 4,711 | |
| Earnings per share (€) | |||
| From continuing operations | [16] | ||
| Basic* | 2.00 | 2.91 | |
| Diluted* | 2.00 | 2.91 | |
| From discontinued operations | [16] | ||
| Basic* | 0.22 | 2.93 | |
| Diluted* | 0.22 | 2.93 | |
| From continuing and discontinued operations | [16] | ||
| Basic* | 2.22 | 5.84 | |
| Diluted* | 2.22 | 5.84 |
* The ordinary shares to be issued upon conversion of the mandatory convertible bond are treated as already issued shares.


Chairman’s Letter
Statements of Income
Bayer Links
Investor Relations

Bookmark this page
E-mail this page
Advanced Search

